



Shares issued due to warrant redemption have been registered

On March 12, Cline Scientific AB ended the subscription period for holders of warrants of series 2020/2021 (TO1 A) and (TO1 B). The redemption of the warrants provided Cline Scientific with SEK 10.1 million before issue costs amounting to SEK 0.1 million.

The issues were registered by the Swedish Companies Registration Office on Wednesday, April 7, 2021. The closing date for the interim shares in Euroclear will be April 15. Thus, the new shares will be in the holder's respective accounts on April 19, 2021.

Through the issue, the number of shares in Cline Scientific of series A has increased by 63,000 to 722,333 and of series B has increased by 2,942,255 to 14,730,404, which means that the total number of shares amounts to 15,452,737. At the same time, the share capital increased by SEK 300,525.50 to SEK 1,545,273.70.

For more information about Cline and their products, please contact:

Patrik Sundh, CEO

Email: patrik.sundh@clinescientific.com

Phone: +46 703-585 088

Cline Scientific AB (publ)

Argongatan 2 C
431 53 MÖLNDAL

Phone: 031-387 55 55

Email: info@clinescientific.com

Website: www.clinescientific.com

About Cline Scientific

Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase